CCT-102 vs. Expectant Management in Delayed Pregnancy Loss (MERMAID)

C

Conceptra Biosciences

Status and phase

Enrolling
Phase 3

Conditions

Early Pregnancy Loss, Delayed Pregnancy Loss

Treatments

Combination Product: CCT-102 A and CCT-102 B

Study type

Interventional

Funder types

Industry

Identifiers

NCT06121063
PRT-CO-CCT-102.001

Details and patient eligibility

About

A Phase 3, multi-center clinical trial of a CCT-102 regimen compared to expectant management to promote uterine evacuation in first trimester non-progressing Delayed Pregnancy Loss (DPL).

Full description

This is a Phase 3, open-label, multi-center study to assess the efficacy of a CCT-102 regimen compared to expectant management for uterine evacuation in first trimester delayed pregnancy loss (DPL). Eligible study participants will have ultrasound documented DPL with estimated gestational age 10 weeks or less. DPL is defined as arrest of embryonic or fetal development, in first trimester, where the cervix is closed and there is no or only slight bleeding. This includes: 1) anembryonic pregnancy, and 2) embryonic demise. Expectant management, which is an accepted treatment protocol recognized in 2018 ACOG Practice Bulletin on Early Pregnancy Loss (ACOG, 2018), consists of patient monitoring with no additional treatment. Eligible participants will be randomized 1:1 to investigational product or expectant management on Day 1. They will be evaluated for the primary endpoint (resolution of DPL) on Study Day 7. All participants will be followed to Day 28.

Enrollment

160 estimated patients

Sex

Female

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Age 18 to 50

  2. Ability to provide informed consent

  3. Hemodynamically stable

  4. Closed cervical os

  5. If fetus exists, clinical observation indicates gestation is no more than 10 weeks

  6. Diagnosis of delayed pregnancy loss, confirmed by ultrasound, based on:

    1. Embryonic demise: no embryonic cardiac activity when embryo measures 7 mm or greater; OR,
    2. Anembryonic pregnancy: mean gestational sac diameter of 25 mm or greater, with no detectable embryo.

Exclusion criteria

  1. Unwillingness or inability to comply with the study protocol and visit schedule
  2. Diagnosis of an incomplete or inevitable abortion including more than slight bleeding at enrollment and/or open os within the prior week.
  3. Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass
  4. Hemoglobin <10 g/dL
  5. Coagulation disorder, inherited porphyrias, and/or current anticoagulants use
  6. Chronic adrenal failure
  7. Concurrent chronic corticosteroid therapy
  8. History of trophoblastic disease
  9. Current presence of an IUD
  10. History of allergy or contraindications to the use to mifepristone, misoprostol, or other prostaglandins
  11. Any condition that, in the opinion of the investigator, makes the patient unsuitable for study entry
  12. Any other current medical condition that jeopardizes the patient's ability to safely participate in the trial

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

160 participants in 2 patient groups

CCT-102 Regimen
Active Comparator group
Description:
CCT-102 A/B regimen
Treatment:
Combination Product: CCT-102 A and CCT-102 B
Expectant management
No Intervention group
Description:
Non-treatment, 'waitful watching'

Trial contacts and locations

19

Loading...

Central trial contact

Sherri Thomas

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems